Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of (a) updates to the programme manual used by the National Institute of Health and Care Excellence including Rapid Access to Managed Access and (b) the introduction of the Innovative Medicines Fund.

The Government is committed to supporting rapid patient access to effective new medicines in a way that is fair to all parties and represents value to the National Health Service. The National Institute for Health and Care Excellence (NICE) plays an important role in supporting patient access to effective new medicines and is able to recommend most new medicines for use in the NHS. Where there is too much clinical uncertainty for NICE to be able to recommend routine funding, it is able to recommend medicines for use through the Cancer Drugs Fund or Innovative Medicines Fund which make promising medicines available to patients while further real-world evidence is collected to inform a final NICE recommendation.

NICE is responsible for the methods and processes it uses in the evaluation of new medicines and the changes that it has recently made to its evaluation processes will enable it to produce faster guidance on simpler, low-risk treatments. NICE and NHS England are exploring options for rapid entry to managed access (REMA) that build on the experience of the Cancer Drugs Fund and Innovative Medicines Fund to support managed access to medicines. NICE has not yet made any changes to its health technology evaluation manual related to REMA.